Direct targeting of EGFR is a promising therapeutic strategy for breast cancers with abnormalities in this pathway and may be beneficial in breast cancer patients who cannot tolerate surgery or traditional chemotherapy, or in advanced recalcitrant cases with poor prognoses [23], [24]. This evidence concerns the gene EGFR and breast carcinoma.